-- Direct subsidiary Samsung Peptide AG acting as formal offeror of the 
      public tender offer 
 
   -- Publication of offer prospectus follows pre-announcement on July 20, 2026 
 
   -- Largest individual shareholder committed to tender all of its PolyPeptide 
      shares into offer 
 
   -- Main offer period expected to last from Sept. 15 to Oct. 12, 2026 

INCHEON, South Korea and ZUG, Switzerland, Aug. 31, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization $(CDMO)$, through its direct Swiss subsidiary Samsung Peptide AG ("Samsung Peptide"), today published the tender offer prospectus ("Offer Prospectus") for all publicly held registered shares of PolyPeptide Group AG ("PolyPeptide").

PolyPeptide shareholders will receive CHF 44.31 net in cash for each PolyPeptide share, representing an implied aggregate equity value of approximately CHF 1.46 billion. The offer price represents a 40% premium compared with the unaffected price of PolyPeptide's shares on the SIX Swiss Exchange ("SIX") as of April 10, 2026, which was the last trading day prior to the publication of the first media speculation regarding a potential acquisition of PolyPeptide. The offer price represents a premium of 11.6% compared with the volume-weighted average share price over the last 60 trading days prior to the pre-announcement on July 20, 2026.

The Board of Directors of PolyPeptide, acting through its independent and non-conflicted members, unanimously recommends that PolyPeptide's shareholders accept the offer. The recommendation is further supported by an independent fairness opinion from IFBC AG.

Draupnir Holding B.V., PolyPeptide's largest individual shareholder, who holds approximately 55.65% of the total PolyPeptide shares outstanding (excluding treasury shares), has undertaken to tender all of its shares into the offer.

The main offer period commences on Sept. 15, 2026 and is expected to end on Oct. 12, 2026 at 4 p.m. Swiss time. The offer is subject to a minimum acceptance threshold of 662/3% on a fully diluted share count basis (excluding treasury shares), applicable regulatory approvals, and other customary conditions described in the Offer Prospectus. The Offer Prospectus and further offer documentation is available on https://samsungbiologics.com/offer.

Following the settlement of the offer Samsung Peptide intends to pursue a squeeze-out of any remaining minority shareholders and to delist PolyPeptide's shares from the SIX.

Media Contact

samsungbiologics@info.sodali.com

+44 20 7100 6451

Victoria Palmer-Moore

vpm@sodali.com

Sam Austrums

sam.austrums@sodali.com

Peter Lambie

peter.lambie@sodali.com

Contact for Institutional Investors and Retail Shareholders

polypeptide-offer@investor.sodali.com

Institutional investor hotline: +44 204 5136928

Retail investor hotline: +41 43 550 72 52

Sodali has been mandated by Samsung Biologics on behalf of Samsung Peptide as information agent in connection with this offer.

About Samsung Peptide

Samsung Peptide AG, Zug, Switzerland, is a direct subsidiary of Samsung Biologics and was established to act as the formal offeror of the offer.

About Samsung Biologics

Samsung Biologics Co., Ltd., Incheon, Republic of Korea (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.

With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 from the acquisition of a manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. Samsung Biologics has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities.

Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.

By implementing the ExellenS$(TM)$ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity.

Samsung Biologics' global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. Samsung Biologics is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, please visit https://samsungbiologics.com.

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries ("PolyPeptide") is a specialized contract development and manufacturing organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S., and India. PolyPeptide's shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.

Disclosure Notice

The Offer Prospectus, which has been published today, and additional offer documentation is available at https://samsungbiologics.com/offer.

The public tender o er is subject to customary terms and conditions as well as regulatory approvals and is currently expected to be completed by the end of 2026.

This publication does not constitute a prospectus or a similar notice according to articles 35 et seqq. and 69 of the Swiss Financial Services Act, is for information purposes only and does not constitute an offer document or an offer of securities for purchase or subscription, nor a solicitation of an offer to buy or subscribe for securities, in any jurisdiction. The terms and conditions of the tender offer are set out exclusively in the Offer Prospectus, published in accordance with applicable Swiss takeover law, including the Swiss Financial Market Infrastructure Act and the Takeover Ordinance. Investors and holders of PolyPeptide shares are advised to carefully read the Offer Prospectus, as well as all other documents relating to the tender offer, as they contain important information about the offer.

Offer Restrictions

General

The public tender offer for the registered shares with a nominal value of CHF 0.01 each of PolyPeptide as described in the documents available on this website (the "Offer") will not be made, directly or indirectly, in any country or jurisdiction in which it would be illegal or otherwise violate any applicable laws or regulations, or which would require Samsung Biologics Co., Ltd. ("Samsung Biologics"), or any of its direct or indirect subsidiaries, including Samsung Peptide to change or amend the terms or conditions of the Offer in any way, or to submit any additional filing to any governmental, regulatory or other authority, or to perform any additional action in relation to the Offer. It is not intended to extend the Offer to any such country or jurisdiction. Any documents relating to the Offer must not be distributed in or sent to any such country or jurisdiction and must not be used for the purpose of soliciting the sale or purchase of securities of PolyPeptide by any person or entity resident or incorporated in any such country or jurisdiction. The terms and conditions of the Offer have been and/or will be published in the Offer documentation. Please visit https://samsungbiologics.com/offer for more information.

Shareholders of PolyPeptide should review the Offer Prospectus and all other Offer documents carefully. The Offer may not be accepted before the expiration of a cooling-off period of ten (10) SIX Swiss Exchange trading days (if not extended by the Swiss Takeover Board), which will run from September 1, 2026.

According to the laws of Switzerland, PolyPeptide shares tendered into the Offer may generally not be withdrawn after they are tendered except under certain circumstances, in particular in case a competing offer for PolyPeptide shares is launched.

United States of America

The Offer will be made for the registered shares of PolyPeptide, a Swiss company whose shares are listed on the SIX, and is subject to Swiss disclosure and procedural requirements, which are different from those of the United States of America (U.S.).

The Offer will be made in the U.S. pursuant to Section 14(e) of, and Regulation 14E under, the U.S. Securities Exchange Act of 1934, as amended (the U.S. Exchange Act), subject to the exemption provided by Rule 14d-1(c) under the U.S. Exchange Act (the Tier I Exemption) and Rule 14e-5(b)(10) under the U.S. Exchange Act and any exemptions that may be granted by the U.S. Securities and Exchange Commission (SEC), and otherwise in accordance with the requirements of Swiss law. Accordingly, the Offer will be subject to disclosure and other procedural requirements, including with respect to withdrawal rights, settlement procedures and timing of payments that are different from those applicable under U.S. domestic tender offer procedures and laws.